Wencke Walter, Head of Innovation at Munich Leukemia Laboratory (MLL) together with the Research and Development Team are investigating the role of the 6-base genome to develop workfows that enable the detection of epigenetic patterns in leukemia patients. Early in their journey the team at MLL praise the biomodal technology for its simplicity, uniformity, and depth of sequencing coverage. Making it a promising tool for enhancing patient satisfaction and biomarker discovery
In this study this far, the duet multiomics solution evoC has helped their researchers to understand:
- How the epigenetic landscape can reveal changes during disease development.
- The potential to improve disease subtyping via integrating methylation patterns and genomic variants.
- How this initial research now enables the team to investigate more targeted sequencing approaches focused on specific mutations.
